<DOC>
	<DOCNO>NCT02607111</DOCNO>
	<brief_summary>This study evaluate optimal dosage safety Dalteparin use anticoagulant hemodialysis therapy .</brief_summary>
	<brief_title>A New Anticoagulation Method Using Dalteparin Quotidian Nocturnal Home Hemodialysis Patients</brief_title>
	<detailed_description>Routine anticoagulation require hemodialysis treatment . In North America , anticoagulant choice hemodialysis therapy unfractionated heparin ( UFH ) , whereas Western Europe , low molecular weight heparin ( LMWH ) . Dalteparin commonly use Canada approve use in-centre thrice-weekly hemodialysis population fix dose 5000 unit . However , publish study assess use dalteparin home quotidian and/or nocturnal hemodialysis therapy . Patients frequent hemodialysis nocturnal hemodialysis home convert Dalteparin Heparin 4 week evaluate optimal dosage ass safety population</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>Currently undergo shorthour daily nocturnal hemodialysis home dialysis program London Health Sciences Centre . Patients increase bleed risk Currently full dose anticoagulant Active bleed Diabetic retinopathy Active cancer receive treatment within past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Dalteparin</keyword>
	<keyword>Dosage</keyword>
	<keyword>Home Hemodialysis</keyword>
</DOC>